Latest Biotech Startup Funding Rounds

Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.

This page showsSector: Biotech
Rounds
153
Jul 18 – Oct 15, 2026
Disclosed funding
$5.2B
123 disclosed amounts
Median round
$20M
Of disclosed amounts
153 rounds
Funding rounds
CompanyAmountRoundSectorCountryInvestorsAnnounced
AitiologicBiotech · AustriaCompany profile

A precision-medicine company developing liquid-biopsy tests that interpret cell-free DNA signals for early disease risk assessment.

A precision-medicine company developing liquid-biopsy tests that interpret cell-free DNA signals for early disease risk assessment.

€6.4MSeedBiotechAustriaInvestors
RegCell, Inc.Biotech · United StatesCompany profile

RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development.

RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development.

$44MSeries ABiotechUnited StatesInvestors
ReEmerge, Inc.Healthtech · United StatesCompany profile

ReEmerge is developing Cognitive Network Restoration Therapy (CNRT) for people with chronic cognitive impairment after brain injury. The treatment targets underactive but viable neural circuits in the central thalamus to restore function across disrupted brain networks; the company is advancing this restorative approach through clinical development.

ReEmerge is developing Cognitive Network Restoration Therapy (CNRT) for people with chronic cognitive impairment after brain injury. The treatment targets underactive but viable neural circuits in the central thalamus to restore function across disrupted brain networks; the company is advancing this restorative approach through clinical development.

$37MSeries ABiotech, HealthtechUnited StatesInvestors
EvvyHealthtech · United StatesCompany profile

Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health.

Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health.

$40MSeries BBiotech, HealthtechUnited StatesInvestors
AOI Biosciences, Inc.Biotech · JapanCompany profile

A biotechnology company developing antibody diagnostics and drug-discovery methods for difficult protein targets.

A biotechnology company developing antibody diagnostics and drug-discovery methods for difficult protein targets.

UndisclosedEquity issuance and secondary transferUndisclosedBiotechJapanInvestors
Ferm LabsFoodtech · SwitzerlandCompany profile

Ferm Labs develops fermentation-based flavour ingredients for food manufacturers, using fermentation science to deepen savoury taste and help reformulate products with less salt and fewer additives.

Ferm Labs develops fermentation-based flavour ingredients for food manufacturers, using fermentation science to deepen savoury taste and help reformulate products with less salt and fewer additives.

€3MSeedBiotech, FoodtechSwitzerlandInvestors
Shennon BiotechnologiesBiotech · United StatesCompany profile

Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.

Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.

$12MFundingUndisclosedBiotechUnited StatesInvestors
Athernal BioBiotech · United KingdomCompany profile

Targeted immunotherapies aim to stop blood cancers by treating high-risk clonal hematopoiesis before malignancy emerges.

Targeted immunotherapies aim to stop blood cancers by treating high-risk clonal hematopoiesis before malignancy emerges.

~£700KGrantUndisclosedBiotechUnited KingdomInvestors
EthrisBiotech · GermanyCompany profile

Ethris develops inhaled mRNA therapeutics and vaccines for respiratory diseases, using proprietary RNA stabilization and nanoparticle delivery platforms.

Ethris develops inhaled mRNA therapeutics and vaccines for respiratory diseases, using proprietary RNA stabilization and nanoparticle delivery platforms.

€30MHERA Invest financingUndisclosedBiotechGermanyInvestors
Connecta TherapeuticsBiotech · SpainCompany profile

Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome.

Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome.

€3.1MClinical development financingUndisclosedBiotechSpainInvestors

Active investors in this selection

All investors →

Ranked by rounds participated in · From Jul 18, 2026

  1. 1
    Eli Lilly and Company

    BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences

    10rounds
    0led
  2. 2
    RA Capital Management

    Circle Pharma, Inc., Solstice Oncology, Superluminal Medicines

    8rounds
    2led
  3. 3
    Y Combinator (YC)

    Molagri, Sensible Biotechnologies, WonderTx

    6rounds
    0led
  4. 4
    Catalio Capital Management

    BigHat Biosciences, Basecamp Research, Enveda

    6rounds
    2led
  5. 5
    Oxford Science Enterprises

    OMass Therapeutics, ReEmerge, Inc., Vivid Dx

    5rounds
    0led

Latest digests

Archive →

Explore published rounds while the next edition is being prepared.

Browse rounds by topic